Epidermal growth factor receptor/HER2/insulin-like growth factor receptor signalling and oestrogen receptor activity in clinical breast cancer.
about
GREB1 functions as a growth promoter and is modulated by IL6/STAT3 in breast cancerPhosphorylation of caspase-7 by p21-activated protein kinase (PAK) 2 inhibits chemotherapeutic drug-induced apoptosis of breast cancer cell linesSafety, tolerability, and pharmacokinetics of the anti-IGF-1R monoclonal antibody figitumumab in patients with refractory adrenocortical carcinomaA Role for Notch Signalling in Breast Cancer and Endocrine ResistanceInsulin-like growth factor and epidermal growth factor signaling in breast cancer cell growth: focus on endocrine resistant diseaseIGF-IR Targeted Therapy: Past, Present and FutureMolecular Pathways: Clinical Applications and Future Direction of Insulin-like Growth Factor-1 Receptor Pathway BlockadeAn Experimental Analysis of the Molecular Effects of Trastuzumab (Herceptin) and Fulvestrant (Falsodex), as Single Agents or in Combination, on Human HR+/HER2+ Breast Cancer Cell Lines and Mouse Tumor XenograftsEstrogen utilization of IGF-1-R and EGF-R to signal in breast cancer cells.Novel actions of estrogen to promote proliferation: integration of cytoplasmic and nuclear pathways.Pathways to tamoxifen resistance.Mechanisms of acquired resistance to endocrine therapy in hormone-dependent breast cancer cells.Modeling ERBB receptor-regulated G1/S transition to find novel targets for de novo trastuzumab resistanceDual blockade of epidermal growth factor receptor and insulin-like growth factor receptor-1 signaling in metastatic pancreatic cancer: phase Ib and randomized phase II trial of gemcitabine, erlotinib, and cixutumumab versus gemcitabine plus erlotiniIdentification of four novel phosphorylation sites in estrogen receptor alpha: impact on receptor-dependent gene expression and phosphorylation by protein kinase CK2.Epidermal growth factor receptor signalling in human breast cancer cells operates parallel to estrogen receptor α signalling and results in tamoxifen insensitive proliferationTherapeutic potential of the dual EGFR/HER2 inhibitor AZD8931 in circumventing endocrine resistance.3,3'-Diindolylmethane (DIM) inhibits the growth and invasion of drug-resistant human cancer cells expressing EGFR mutantsGiven breast cancer, does breast size matter? Data from a prospective breast cancer cohort.The molecular mechanisms underlying the pharmacological actions of ER modulators: implications for new drug discovery in breast cancer.Dopamine, by acting through its D2 receptor, inhibits insulin-like growth factor-I (IGF-I)-induced gastric cancer cell proliferation via up-regulation of Krüppel-like factor 4 through down-regulation of IGF-IR and AKT phosphorylationOverexpression of CD44 accompanies acquired tamoxifen resistance in MCF7 cells and augments their sensitivity to the stromal factors, heregulin and hyaluronan.Anti-IGF-1R monoclonal antibody inhibits the carcinogenicity activity of acquired trastuzumab-resistant SKOV3Insulin-like growth factor-2 (IGF-2) activates estrogen receptor-α and -β via the IGF-1 and the insulin receptors in breast cancer cells.The turnover of estrogen receptor α by the selective estrogen receptor degrader (SERD) fulvestrant is a saturable process that is not required for antagonist efficacyThe role of the insulin-like growth factor-1 system in breast cancerEpidermal growth factor receptor expression in urinary bladder cancerIn silico discovery and validation of potent small-molecule inhibitors targeting the activation function 2 site of human oestrogen receptor αFulvestrant-induced expression of ErbB3 and ErbB4 receptors sensitizes oestrogen receptor-positive breast cancer cells to heregulin β1Headway in resistance to endocrine therapy in breast cancer.Therapeutic advances in BIG3-PHB2 inhibition targeting the crosstalk between estrogen and growth factors in breast cancererbB3 recruitment of insulin receptor substrate 1 modulates insulin-like growth factor receptor signalling in oestrogen receptor-positive breast cancer cell lines.Mouse models of estrogen receptor-positive breast cancerDirect involvement of breast tumor fibroblasts in the modulation of tamoxifen sensitivityNetwork analysis of an in vitro model of androgen-resistance in prostate cancer.Preclinical and clinical studies of estrogen deprivation support the PDGF/Abl pathway as a novel therapeutic target for overcoming endocrine resistance in breast cancer.Immunohistochemical validation of multiple phospho-specific epitopes for estrogen receptor alpha (ERalpha) in tissue microarrays of ERalpha positive human breast carcinomasSmall-molecule inhibitors of ERK-mediated immediate early gene expression and proliferation of melanoma cells expressing mutated BRafBreastDefend enhances effect of tamoxifen in estrogen receptor-positive human breast cancer in vitro and in vivo.The impact of PTEN tumor suppressor gene on acquiring resistance to tamoxifen treatment in breast cancer patients
P2860
Q21560759-06110A81-600D-42FB-A7E8-BC8ABBF23E95Q24301847-6347B4E6-5447-4719-8AB9-2696638CAA27Q24607285-3169E68C-BCF5-43E0-A0E8-DFB552270C22Q26765912-51707CD2-C5BD-4B9A-8594-6442D76E7843Q26800001-7D4BA2F0-A00E-44AB-ADE8-E79B5A3AB0AFQ28082127-0525FED2-08B6-4E90-B094-7050A55554C0Q28088432-0B14DE6E-86F7-4178-9157-24A4E8F4D956Q28468447-F26DA13B-BBAD-4933-A632-15B36546748DQ30433113-65B00CBC-4490-43B7-8682-7EAF8B1CE149Q30435726-EF6BBF9D-5FA4-441A-B06D-F08FB2B7B372Q30441001-DC127B04-EF1B-4BB6-8CE7-90AAB7E60AA2Q30441321-C894A76F-1386-496E-B7C8-9720EEF5C852Q33396832-70358127-BF98-441C-BACC-9D45FA41DFC5Q33416585-BDE3D81B-13AD-423D-82DD-FEA15D8CC334Q33521519-3A6F421C-C6E4-4B80-9ABF-295E184DCBDDQ33612070-DF110753-6873-47FE-81D6-27D077F94491Q33648503-8194453B-17A7-4DED-B49E-7D1E5D7CDC3DQ33937876-D5907975-5116-4BCC-BE63-148AC62AD64EQ34303594-244AACA6-9695-43D6-9F09-328A70BA325FQ34311300-729C2B8A-5F33-4F02-885C-CF92351E14F0Q34358346-9E504441-0620-4F1E-B5D8-2634180F8473Q34435089-465CE69C-9788-49A2-9949-F75159A0442EQ34659512-D8E90A70-AEFB-4ED3-ACD3-0C9D7D71ACC9Q34970719-D1E67C2D-59C4-4FA2-8FC6-F396E60C6D22Q35027844-0300AF10-F05A-4F3E-ADDC-80F3C640C1C5Q35105295-9AAA8F9A-26B4-44FB-B658-8511C305565AQ35125725-EB2D0281-C215-436E-8C65-DCD6441DCC30Q35180278-D522D265-CFA6-4ADB-B8E2-87C9163E6CD2Q35558954-EE1DAE8D-2F99-4F0D-8127-2E731DC4877AQ35667708-ADCD238E-E686-4D11-93A7-3EC9D12C0A91Q35674177-68FAE330-F19F-49F9-A0E2-DF2D34849ECBQ35683561-66B90FA2-4512-429C-8CCC-D9192A7326C4Q35685892-955B0500-6925-4934-A37B-17FFD214C063Q35757179-D4AAB9F4-2F5C-483C-9DBC-A70B05FF2794Q35836735-70A834C3-D61C-44F7-8498-982A29545092Q36245376-C52A2C53-8B77-45FD-80C2-77B4941C5459Q36251310-BAD938D1-0166-4818-8FF6-E07682A2AE9BQ36276136-F41F1796-7907-45C7-BD3E-CE6AB75D6FCDQ36283422-EB9DE715-986A-4215-85C4-86F57005FE84Q36312142-7D606307-7037-48CA-B63A-715FBEB698F5
P2860
Epidermal growth factor receptor/HER2/insulin-like growth factor receptor signalling and oestrogen receptor activity in clinical breast cancer.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Epidermal growth factor recept ...... ity in clinical breast cancer.
@ast
Epidermal growth factor recept ...... ity in clinical breast cancer.
@en
type
label
Epidermal growth factor recept ...... ity in clinical breast cancer.
@ast
Epidermal growth factor recept ...... ity in clinical breast cancer.
@en
prefLabel
Epidermal growth factor recept ...... ity in clinical breast cancer.
@ast
Epidermal growth factor recept ...... ity in clinical breast cancer.
@en
P2093
P50
P356
P1476
Epidermal growth factor recept ...... vity in clinical breast cancer
@en
P2093
Gutteridge E
Nicholson RI
Robertson JF
P304
P356
10.1677/ERC.1.01005
P478
12 Suppl 1
P577
2005-07-01T00:00:00Z